Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mirati Therapeutics Inc.
This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
Unresectable or metastatic disease
Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
Adequate organ function
You may not be if
History of intestinal disease or major gastric surgery or inability to swallow oral medications
